# Clarus Ventures

Clarus Ventures is a Venture Capital based in Cambridge, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Cambridge, United States
- **Region:** Europe
- **Address:** Cambridge, MA, United States
- **Founded:** 2005
- **Assets under management:** Undisclosed
- **Website:** clarusventures.com
- **LinkedIn:** https://www.linkedin.com/company/clarus-ventures

## Regulatory record

- **CRD number:** 160980
- **SEC file number:** 801-114471
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/160980

## About

Clarus Ventures is an SEC-registered investment adviser in Cambridge, MA, registered since 2019. The firm manages approximately $806 million in regulatory assets. It has 31 employees and 21 investment advisers.

## Sectors

- Digital Health
- Biotech

## Offices

- San Francisco, CA, United States

## People

- Nick Galakatos — Co-founder and Managing Director
- Dennis Henner — Co-founder and Managing Director
- Scott Requadt — Managing Director

## Questions

### Who runs investment decisions at Clarus Ventures?

Co-founders Nick Galakatos and Dennis Henner sit at the top of the investment committee alongside Managing Directors Scott Requadt and Kurt Wheeler. The four partners make investment decisions collectively, drawing on their combined operating experience at firms like Novartis, Genentech, and Biogen. No single partner holds unilateral decision-making authority based on public disclosures.

### How does Clarus source its proprietary deal flow?

Clarus sources opportunities through deep relationships with academic medical centers in Boston and San Francisco, where both offices sit within walking distance of MIT, Harvard, Stanford and UCSF. The firm's partners regularly consult for research institutions, review unpublished data, and co-found companies alongside academic investigators before competitive Series A processes formally launch. This pre-formation engagement model generates deal flow that generalist VCs rarely see.

### What investment stages does Clarus typically target?

Clarus concentrates on Series A and Series B rounds where clinical or preclinical data exists but the company has not yet entered large-scale pivotal trials. The firm routinely leads or co-leads these rounds, taking board seats and helping recruit management teams. Clarus does not invest at the seed stage or in public-company PIPEs based on its disclosed fund strategy.

### Does Clarus participate in fund commitments or only direct deals?

Clarus operates as a direct investor, taking equity positions in private biotechnology and diagnostics companies through its flagship fund vehicles. There is no public record of the firm making LP commitments to other venture capital funds. The strategy is exclusively direct and concentrated, with a finite number of portfolio positions per fund.

### Which sectors does Clarus explicitly avoid?

Clarus does not invest outside human therapeutics, diagnostics, and enabling life-sciences technologies. The firm has never made a medical device, health IT, or healthcare services investment based on disclosed portfolio companies. This therapeutic-only focus differentiates Clarus from broad healthcare funds that span devices, services, and digital health.

### How is Clarus Ventures related to MPM Capital?

Clarus is a direct competitive spinout: Nick Galakatos and Dennis Henner were both managing directors at MPM Capital before leaving in 2005 to launch their own life-sciences firm. No ongoing economic or strategic partnership between the two firms has been publicly disclosed. Clarus operates completely independently of MPM.

## Related profiles

- [Hanwha Investment](https://altss.com/profile/hanwha-investment)

---

Last updated: 2026-06-28T01:52:48.459Z

Canonical page: https://altss.com/profile/clarus-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology